There is one clinical trial.
A randomized, open-label, 2 arm, pilot trial of Lambda 180 mcg administered subcutaneously once weekly, for up to two weeks (2 injections at most), in addition to standard supportive care, compared to standard supportive care alone, in a population of COVID-19 infected patients. patients will be randomized according to 1:1 ratio to one of the 2 trial arms: Lambda 180 mcg S.C + standard care (intervention arm) or standard care only (control arm).
Description: The duration of viral shedding in days since initial diagnosis, as determined by RT-PCR to COVID-19.Measure: Viral shedding in days since initial diagnosis Time: 21 days
Description: Rate of treatment-emergent and treatment-related severe adverse events (SAEs)Measure: Rate of adverse events and severe adverse events Time: 21 days from entry
Description: the time (in hours) from initiation of trial treatment (Lambda or standard care) until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours.Measure: Time to clinical recovery Time: 72 Hours
Description: Requirement for non-invasive (bipap) or mechanical ventilationMeasure: Rate of non-invasive or mechanical ventilation Time: 28 Days
Description: length of hospital stay from admission to dischargeMeasure: Length of hospital stay Time: 28 Days
Description: All-cause mortalityMeasure: All-cause mortality Time: At day 28 following admission to the hospital
Description: Rate of undetectable COVID-19 virus levels at different daysMeasure: Undetectable COVID-19 virus levels Time: At days 7,14 and 21 from admission
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports